Clinical trials: Transfusion Related Lung Injury
Transfusion Reactions
Mild Pulmonary Function Changes With Transfusion
The purpose of the study is to determine whether transfusion is associated with mild pulmonary changes.
- Trial name
- NCT00681954
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- University of California, San Francisco
Acute Lung Injury
Transfusion-related Acute Lung Injury: a Prospective Cohort Study in Critically Ill Children
Transfusions cause more adverse events in children than in adults. Patients in pediatric intensive care units (PICU) are particularly exposed to transfusions of plasma-rich blood products (red blood cell (RBC), plasma and…
- Trial name
- TRALI (NCT02613377)
- Testing
- Blood transfusion
- Where
- 4 sites in Canada
- Volunteers
- 717 people
- Sponsor
- St. Justine's Hospital
Trauma
Pragmatic, Randomized Optimal Platelet and Plasma Ratios
Pragmatic, Randomized, Optimal Platelet and Plasma Ratios (PROPPR)is a Phase III trial designed to evaluate the difference in 24-hour and 30-day mortality among subjects predicted to receive massive transfusion ([MT] (defined as…
- Trial name
- PROPPR (NCT01545232)
- Testing
- 1:1:1 Blood Transfusion Ratio, 1:1:2 Blood Transfusion Ratio
- Where
- 12 sites in United States, Canada
- Volunteers
- 680 people
- Sponsor
- The University of Texas Health Science Center, Houston
Bleeding, Cardiac Defect
ZEPLAST- PED: ZEro_PLASma Trial in Small Infants Undergoing Cardiac Surgery
In pediatric patients (newborns and infants weighing less than 10 kg) undergoing cardiac surgery with extracorporeal circulation postoperative bleeding represents a known complication with a significant impact on outcome.
- Conditions
- Bleeding, Cardiac Defect, Surgery--Complications, Fibrinogenopenia; Acquired
- Trial name
- ZEPLAST-PED (NCT04434001)
- Testing
- Fibrinogen Concentrate Human, Prothrombin Complex Concentrate, Fresh Frozen Plasma
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- IRCCS Policlinico S. Donato
Transfusion Related Acute Lung Injury
A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components
This study is a prospective, non-randomized sequential cohort, open label, multi-center, non-inferiority, Phase IV surveillance study following transfusion of INTERCEPT PCs.
- Trial name
- PIPER (NCT02549222)
- Testing
- Standard of Care
- Where
- 15 sites in United States
- Volunteers
- 2,291 people
- Sponsor
- Cerus Corporation